This approach would avoid the problem of rejection seen with both allogeneic transplantation of islets and pancreas and would release T1D patients from daily insulin injections, the risk of hypo- and hyperglycaemia episodes and the long-term chronic complications that lower quality of life and cost the community millions of dollars in patient care. This evidence concerns the gene INS and type 1 diabetes mellitus.